Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b lebrikizumab study in moderate-to-severe atopic dermatitis
NL-OMON59323Phase 3Completed
- Sponsor
- Almirall
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Primary endpoint: Percentage of participants achieving EASI score ≤7 at Week 24. Started Jul 2024; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON59323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59323.